If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
KE Holdings Inc. (BEKE)
RedBall Acquisition Corp. (RBAC.U)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NavSight Holdings (NSH.U)
dMY Technology Group II (DMYD.U)
Duck Creek Technologies, Inc. (DCT)
CureVac B.V. (CVAC)
Dragoneer Growth Opportunities (DGNR.U)
Northern Genesis Acquisition (NGA.U)
Inhibrx, Inc. (INBX)
Harmony Biosciences Holdings, Inc. (HRMY)
Priced IPO
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
More companies

Genetron Holdings Limited (GTH)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. They have developed a comprehensive product and service portfolio that covers the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. According to Frost & Sullivan, they are one of the most advanced precision oncology companies that cover the full-cycle of cancer care. They provide comprehensive diagnostic products and services that cover eight out of the top ten major cancer types in China, capable of analyzing from focused gene panels to whole exome of approximately 21,000 genes. Depending on the nature of cancer and service types, they offer tissue biopsy, liquid biopsy, or both, providing great flexibility to patients and physicians to achieve the best clinical outcome. On the frontier of early screening, they have developed a leading technology platform and achieved breakthrough with their proprietary HCCscreenTM assays that enable early detection and intervention of liver cancer. They also offer a high quality, end-to-end comprehensive genomic profiling solution for global biopharmaceutical companies to support their research and drug development.
Sizhen Wang Evan Ce Xu
Employees Founded
697 2015


Address: 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway Changping District, Beijing, People’s Republic of China

Telephone: +86 10 5090-7500

Web page:

IPO information

Expected Date 6/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $1104.5
Revenues (MM) $446.9
Net Income (Loss) (MM) $-92.7


What do you think will happen with the GTH share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 13
Shares Revised (MM) 16
Expected offer amount (MM) $200
Realized offer amount(MM) $256
Credit Suisse/ CICC
BTIG/ Canaccord Genuity

Sector: Healthcare

Tweets about $GTH

Tweets volume:

RT volume:


Google Trends Stats